Tucatinib has shown significant efficacy in treating advanced HER2+ breast cancer, including cases with brain metastases. In vitro studies identified time-dependent inhibition (TDI) of CYP3A4 by tucatinib, though with low inactivation efficiency. This poster highlights the mechanism behind tucatinib’s interaction with CYP3A4.
Click here to download this scientific poster!
Interested in learning more about our DMPK services? Click here for an overview of our services and access to frequently asked questions.
